Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

NCT06864169 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT06864169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 1, 2025
Completion date
January 4, 2029
Enrollment
160 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer